DeutschNewstral
Article
Mmarketwatch.com on 2016-10-24 17:20
Inovio Pharma stock down 14% after FDA puts clinical hold on proposed late-stage trial
Related news
- MConcert Pharma stock drops 10% after FDA puts hair loss drug on clinical holdmarketwatch.com
- MHookipa Pharma jumps 40% after FDA approval of clinical testsmarketwatch.com
Inovio stock plunges more than 34% as FDA puts Covid-19 vaccine trial on holdbizjournals.com- FDA puts clinical hold on Inovio's late-stage immunotherapy studybizjournals.com
- MSolid Biosciences shares plunge as FDA puts study on clinical holdmarketwatch.com
- MRegeneron stock slumps nearly 2% after FDA puts hold on midstage clinical trialmarketwatch.com
U.S. FDA puts on hold Covaxin’s phase 2/3 clinical trialsThe Hindu- MInovio Pharma stock slips as AstraZeneca unit scales back agreementmarketwatch.com
FDA protects Big Pharmakentucky.com- MInovio Pharma stock fluctuates after results, vaccine updatemarketwatch.com
- Durham pharma receives FDA approvalbizjournals.com
- FDA lifts suspension of Juno clinical trialbizjournals.com
- FDA clears ALung device for clinical trialsbizjournals.com
FDA approves new Baxter clinical nutrition injectionsdailyherald.com- Inovio shares rise after FDA OK to complete testing of its Covid-19 vaccine candidatebizjournals.com
Clinuvel Pharma jumps 47pc on FDA approvalSydney Morning Herald- FDA approves Princeton pharma company's cancer drugbizjournals.com
- Jacksonville pharma company gets FDA approvalbizjournals.com
Pharma, The FDA, And Social MediaForbes- Pharma Critic Skewers Homeopathy At FDA HearingForbes